A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
Authors
Keywords
-
Journal
BMC CANCER
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-18
DOI
10.1186/s12885-021-08441-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Annual report to the nation on the status of cancer, part I: National cancer statistics
- (2020) S. Jane Henley et al. CANCER
- Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life
- (2019) Rossella De Luca et al. OncoTargets and Therapy
- Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).
- (2019) Fumikata Hara et al. JOURNAL OF CLINICAL ONCOLOGY
- A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer
- (2019) Eva Ciruelos et al. ONCOLOGIST
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis
- (2018) Reshma L Mahtani et al. Cancer Management and Research
- Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab -Paclitaxel
- (2018) Norbert Marschner et al. Clinical Breast Cancer
- Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project
- (2018) Marina E. Cazzaniga et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology
- (2018) Arti Hurria et al. Clinical Breast Cancer
- A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer
- (2017) Shigeru Yamamoto et al. Breast Cancer
- Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials
- (2017) Yun Liu et al. Oncotarget
- An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.
- (2017) C. B. Brezden et al. JOURNAL OF CLINICAL ONCOLOGY
- Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study
- (2016) Minish M. Jain et al. BREAST CANCER RESEARCH AND TREATMENT
- The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis
- (2015) Caihua Liang et al. BMC CANCER
- Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
- (2015) C. Paoletti et al. CLINICAL CANCER RESEARCH
- TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
- (2015) A. Forero-Torres et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
- (2015) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
- (2015) Alessandra Fabi et al. Drug Design Development and Therapy
- Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
- (2015) Raffaella Palumbo et al. Drug Design Development and Therapy
- Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Versus Functional Age
- (2014) A. Hurria et al. ONCOLOGIST
- nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
- (2013) Joyce O’Shaughnessy et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre
- (2013) S. Dent et al. Current Oncology
- A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline
- (2012) Anantbhushan A Ranade et al. Asia-Pacific Journal of Clinical Oncology
- Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
- (2012) William J. Gradishar et al. Clinical Breast Cancer
- US Food and Drug Administration Approval Overview in Metastatic Breast Cancer
- (2012) Patricia Cortazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: A post-hoc analysis
- (2011) Matti Aapro et al. BREAST
- A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
- (2011) Barry Mirtsching et al. Clinical Breast Cancer
- Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer
- (2009) Zhong-Zhen GUAN et al. Asia-Pacific Journal of Clinical Oncology
- Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
- (2009) William J. Gradishar et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started